It’s incredibly important that patients with Hodgkin lymphoma understand their diagnosis, their treatment options, and their prognosis, explained Alison J. Moskowitz, MD, medical oncologist, clinical director, lymphoma inpatient unit, Memorial Sloan Kettering Cancer Center.
It’s incredibly important that patients with Hodgkin lymphoma understand their diagnosis, their treatment options, and their prognosis, explained Alison J. Moskowitz, MD, medical oncologist, clinical director, lymphoma inpatient unit, Memorial Sloan Kettering Cancer Center.
How important is it to engage patients with Hodgkin lymphoma so that they understand their diagnosis and their treatment options?
I think it’s incredibly important that patients understand their diagnosis and what the treatment options are and what their prognosis is. I think that the treatment options that we have to offer patients are often not straightforward and now black and white where there’s one right or wrong answer. Some of it really has to depend upon the patient’s own values and their own choices.
One example of that is when we are offering patients with early stage Hodgkin lymphoma a treatment approach where we’re going to consider either combined modality therapy, where we include radiation therapy or chemotherapy alone. That is an important discussion to have with the patients, because the cure rate with chemotherapy alone for early stage Hodgkin lymphoma is not as high as when we use combined modality therapy. But, by eliminating the radiation, we are reducing long-term toxicity. But there’s a small group of patients who are going to relapse and then going to need much more intense chemotherapy and a stem cell transplant in order to cure their disease at that point.
So, even though the majority of patients still will be cured with chemotherapy alone, it’s an important discussion to have with the patients to make sure they understand what they’re potentially giving up if they’re not getting radiation earlier on in their treatment.
I think it’s perfectly reasonable to avoid radiation for many, many patients, but I think we have to be informing patients why we’re making this choice and have them be a part of that choice as well.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More
Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH
December 6th 2023ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Read More